1311-Instytut MSF Sp. z. o.o. Trials

1311-Instytut MSF Sp. z. o.o.	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Kalinka, Ewa

ARTEST, NCT04869943 / 2021-002176-39: Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer

Terminated

Europe, US, RoW

Enobosarm, VERU-024, Exemestane, Mestane

Veru Inc.

Metastatic Breast Cancer

01/24

ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined with Abemaciclib Compared with Fulvestrant Combined with Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation

Recruiting

400

Europe, Canada, US, RoW

Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib

Sermonix Pharmaceuticals Inc.

Metastatic Breast Cancer

06/25

06/26

FLORA-4, NCT04498117 / 2020-002270-26: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Active, not recruiting

615

Europe, Canada, US, RoW

Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo

CanariaBio Inc., Gynecologic Oncology Group, Iqvia Pty Ltd

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms

09/25

08/27

Be6A Lung-01, NCT06012435: A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer ().

Recruiting

600

Europe, Canada, Japan, US, RoW

sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel

Seagen Inc.

Carcinoma, Non-Small-Cell Lung

07/26

07/28

BA3011-002, NCT04681131: CAB-AXL-ADC Safety and Efficacy Study in Adults with NSCLC

Active, not recruiting

240

Europe, US, RoW

CAB-AXL-ADC, BA3011, PD-1 inhibitor

BioAtla, Inc.

Non-Small-Cell Lung Cancer

08/25

KEYNOTE F82, NCT06205706: BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors

Sep 2024 - Sep 2024 : Data from Part A of P1 portion of the trial studying BI-1910 as single agent for adv solid tumors

Recruiting

1/2

104

Europe, US

BI-1910, Pembrolizumab

BioInvent International AB, Merck Sharp & Dohme LLC

Solid Tumors, Non Small Cell Lung Cancer, Hepatocellular Carcinoma

07/27

11/28

ELEVATE, NCT05563220: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer

Recruiting

1/2

400

Europe, US, RoW

Elacestrant, Alpelisib, Piqray, Everolimus, Afinitor, Ribociclib, Kisqali, Palbociclib, Ibrance, Capivasertib, Truqap, Abemaciclib, Verzenio

Stemline Therapeutics, Inc.

Breast Cancer, Metastatic Breast Cancer

12/24

08/26

NCT04381650 / 2020-004325-23: A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

Active, not recruiting

1/2

Europe, Japan, US, RoW

TAK-981, Pembrolizumab

Takeda, Takeda Development Center Americas, Inc.

Advanced or Metastatic Solid Tumors

11/25

BA3021-001, NCT03504488: CAB-ROR2-ADC Safety and Efficacy Study in Patients with TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

Active, not recruiting

1/2

420

Europe, US, RoW

CAB-ROR2-ADC, BA3021, PD-1 inhibitor

BioAtla, Inc.

Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer

12/24

FIH, NCT04104776 / 2020-004952-14: A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas

Recruiting

1/2

210

Europe, US, RoW

CPI-0209

Constellation Pharmaceuticals

Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma

12/25

03/26

NCT05002868: Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors

Completed

Europe, RoW

RP12146

Rhizen Pharmaceuticals SA

Solid Tumor, Extensive-stage Small-cell Lung Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, Platinum-sensitive Ovarian Cancer, Platinum-Sensitive Fallopian Tube Carcinoma, Platinum-Sensitive Peritoneal Cancer

04/24

Grubiak, Marta

ARTEST, NCT04869943 / 2021-002176-39: Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer

Terminated

Europe, US, RoW

Enobosarm, VERU-024, Exemestane, Mestane

Veru Inc.

Metastatic Breast Cancer

01/24

BA3011-002, NCT04681131: CAB-AXL-ADC Safety and Efficacy Study in Adults with NSCLC

Active, not recruiting

240

Europe, US, RoW

CAB-AXL-ADC, BA3011, PD-1 inhibitor

BioAtla, Inc.

Non-Small-Cell Lung Cancer

08/25

BA3021-001, NCT03504488: CAB-ROR2-ADC Safety and Efficacy Study in Patients with TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

Active, not recruiting

1/2

420

Europe, US, RoW

CAB-ROR2-ADC, BA3021, PD-1 inhibitor

BioAtla, Inc.

Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer

12/24

FIH, NCT04104776 / 2020-004952-14: A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas

Recruiting

1/2

210

Europe, US, RoW

CPI-0209

Constellation Pharmaceuticals

Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma

12/25

03/26



	Diseases Companies Products Productz Mechanisms of Action Sites